Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
12/23/2003Meridian Bioscience Extends Expiration Date of Exchange Offer
CINCINNATI--(BUSINESS WIRE)--Dec. 23, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it is extending the expiration date for its offer to exchange 5% Convertible Subordinated Debentures due 2013 (New Debentures) in the principal amount of $16,000,000 for an equal amount of outstanding 7% Convertible Subordinated Debentures due 2006 (Existing Debentures), and related withdrawal rights, until 12:00 midnight EST on Wednesday, January 28, 2004, unless extended or earlier t... 
 Printer Friendly Version
12/12/2003Meridian Bioscience Extends Expiration Date of Exchange Offer
CINCINNATI--(BUSINESS WIRE)--Dec. 12, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it is extending the expiration date for its offer to exchange 5% Convertible Subordinated Debentures due 2013 (New Debentures) in the principal amount of $16,000,000 for an equal amount of outstanding 7% Convertible Subordinated Debentures due 2006 (Existing Debentures), and related withdrawal rights, until 12:00 midnight EST on Tuesday, December 30, 2003, unless extended or earlier t... 
 Printer Friendly Version
12/11/2003Meridian Bioscience Launches New Flu Test for Physician Offices
CINCINNATI--(BUSINESS WIRE)--Dec. 11, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that it has begun marketing a new physician's office Influenza A&B Test. This rapid test is simple enough to be performed in physicians' offices and small labs. The new product expands Meridian's influenza and RSV testing lines that continue to be in high demand and have been sold to hospital labs for the past two years. This rapid physician's office flu test differentiates between the A an... 
 Printer Friendly Version
12/9/2003Meridian Bioscience Announces New Rapid Test for Stomach Ulcers
CINCINNATI--(BUSINESS WIRE)--Dec. 9, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market ImmunoCard STAT!(R) HpSA, a rapid new test for the diagnosis of Helicobacter pylori (H. pylori) infection. The vast majority of peptic ulcer disease is caused by infection with H. pylori bacteria and, in recent years, effective therapies have become available for eradicating this patho... 
 Printer Friendly Version
11/25/2003Meridian Bioscience to Present at Friedman Billings Ramsey 10th Annual Investor Conference
CINCINNATI--(BUSINESS WIRE)--Nov. 25, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that Bill Motto, Chairman and Chief Executive Officer; Jack Kraeutler, President and Chief Operating Officer; and Rick Eberly, Executive Vice President and General Manager, Meridian Life Science, have been invited to present at the Friedman Billings Ramsey 10th Annual Investor Conference on Tuesday, December 2, 2003 at 9:30 a.m. ET at the Sheraton New York Hotel & Towers in New York City. A... 
 Printer Friendly Version
11/18/2003Meridian Bioscience Reports Fiscal 2003 Year End and Fourth Quarter Operating Results, Declares Regular Quarterly Cash Dividend, Discusses Fiscal 2004 Dividends and Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 18, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today: reported record fiscal 2003 net sales of $65.9 million (up 11% over fiscal 2002) and diluted earnings per share of $0.47 (up 38% over fiscal 2002) and at the upper range of management's guidance; reported record fourth quarter fiscal 2003 net sales of $17.2 million (up... 
 Printer Friendly Version
11/12/2003Meridian Bioscience Announces Exchange Offer for and Plans to Redeem 7% Convertible Subordinated Debentures Due 2006
CINCINNATI--(BUSINESS WIRE)--Nov. 12, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has commenced an offer to exchange $16.0 million principal amount of new Convertible Subordinated Debentures due 2013 for an equal principal amount of its outstanding 7% Convertible Subordinated Debentures due 2006. The new debentures will bear interest at 5% per year, payable semi-annually each March 1 and September 1. The principal amount of the new debentures wi... 
 Printer Friendly Version
10/15/2003Meridian Bioscience Recognized as One of Forbes' 200 Best Growth Companies in America
CINCINNATI--(BUSINESS WIRE)--Oct. 15, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that Forbes has recognized it as one of the "200 Best Growth Companies in America", as reported in their October 27, 2003 edition. The Forbes 200 Best Growth Companies in America list is selected from a database of 3,500 candidates whose last 12-month sales range between $5 million and $600 million. Additional qualification criteria included profitability tests and l... 
 Printer Friendly Version
10/6/2003Meridian Bioscience Awarded Contract to Manufacture Parvovirus Vaccine for National Institutes of Health - NIH
CINCINNATI--(BUSINESS WIRE)--Oct. 6, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has been awarded a contract to manufacture clinical grade recombinant protein Parvovirus B19 vaccine for The National Institutes of Health. Vaccine production will take place at the Company's life science manufacturing facility located at Viral Antigens, Inc. (VAI), Memphis, TN, a wholly owned subsidiary. Under the terms of this contract, National Heart, Lung, and B... 
 Printer Friendly Version
9/26/2003Meridian Bioscience Files Shelf Registration Statement
CINCINNATI--(BUSINESS WIRE)--Sept. 26, 2003--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has filed a universal shelf registration statement with the Securities and Exchange Commission registering an aggregate of $60 million of securities, which includes common stock, preferred stock, debt or other types of securities. The Company stated that it believes this universal shelf registration statement will facilitate its ability to finance its growth strategies through the ... 
 Printer Friendly Version
7/31/2003Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2004
CINCINNATI--(BUSINESS WIRE)--July 31, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today provided the financial community with guidance regarding the Company's fiscal 2004 sales and earnings estimates. Based on the Company's business planning and budgeting activities, for the fiscal year ending September 30, 2004, management expects net sales to be in the range of $71 to $75 million and per share diluted earnings to be between $0.47 and $0.53. The per share estimates assume an increase i... 
 Printer Friendly Version
7/30/2003Meridian Bioscience to Present at Robert W. Baird & Co.'s 2003 Small Cap Conference
CINCINNATI--(BUSINESS WIRE)--July 30, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today announced that Bill Motto, Chairman and Chief Executive Officer; Jack Kraeutler, President and Chief Operating Officer; and Rick Eberly, Executive Vice President and General Manager, Meridian Life Science, have been invited to present at the Robert W. Baird 2003 Small Cap Conference Tuesday, August 5, 2003 at 10:45 a.m. EDT at the Four Seasons Hotel in New York City. A question and answer session wil... 
 Printer Friendly Version
7/24/2003Meridian Bioscience Reports Third Quarter Record Sales, Higher Per Share Earnings, Declares Regular Cash Dividend, and Reaffirms Fiscal 2003 Guidance
CINCINNATI--(BUSINESS WIRE)--July 24, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) Meridian Bioscience, Inc., (Nasdaq:VIVO) today: reported record third quarter sales of $15,693,000, a 5% increase over the same period of the prior fiscal year; reported diluted earnings per share of $0.12, a 9% increase over the same period of the prior fiscal year; reported third quarter operating income of $3,068,000, second highest third quarter earnings in ... 
 Printer Friendly Version
7/21/2003Meridian to Manufacture and Distribute Chagas' Disease Proteins Under License Agreement with Corixa Corporation
CINCINNATI--(BUSINESS WIRE)--July 21, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it will begin production of recombinant Trypanosoma cruzi (Chagas' disease) antigen under a license agreement with Corixa Corporation (Nasdaq:CRXA) in its life science production laboratories located at Viral Antigens, Inc., Memphis, TN (VAI), a wholly owned subsidiary. The unique recombinant polyvalent antigen, known as TcF, will be marketed to diagnostic test manufacturers for use i... 
 Printer Friendly Version
7/1/2003Meridian Bioscience Added to Russell 2000 Index
CINCINNATI--(BUSINESS WIRE)--July 1, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has been added to the Russell 2000(R) Index of small-capitalization stocks. The Russell Indexes were jointly developed by the Frank Russell Company and the New York Futures Exchange to represent investment-grade equities. Meridian's inclusion in the Russell Index is a result of the Frank Russell Company's annual assessment and reconstitution of its U.S. equity indexes. Final a... 
 Printer Friendly Version
6/10/2003Meridian Announces Manufacturing Agreement with Hawaii Biotech, Inc. to Produce Vaccine for Dengue Fever
CINCINNATI--(BUSINESS WIRE)--June 10, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced the signing of its second biopharmaceutical manufacturing agreement for the Company's life science production facility located at Viral Antigens, Inc., Memphis, TN (VAI), a wholly-owned subsidiary. Hawaii Biotech, Inc. has selected VAI to manufacture and supply bulk polyvalent recombinant subunit vaccine for dengue virus 1-4. The bulk vaccine for human clinical studies will be produced in ... 
 Printer Friendly Version
4/24/2003Meridian Bioscience Reports Record Sales, Higher Per Share Earnings, Declares Regular Cash Dividend, and Reaffirms Fiscal 2003 Guidance
CINCINNATI--(BUSINESS WIRE)--April 24, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today: reported all-time record quarterly sales of $16,913,000, a 12% increase over the same period of the prior fiscal year; reported diluted earnings per share of $0.13, a 30% increase over the same period of the prior fiscal year; reported all-time record quarterly operating income of $3,784,000; declared a regular cash dividend of $... 
 Printer Friendly Version
4/9/2003Meridian Announces First Manufacturing Agreement for Its New Life Science Production Facility and Names Richard Eberly Head of Newly Established Life Science Business Unit
CINCINNATI--(BUSINESS WIRE)--April 9, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has signed its first manufacturing agreement for the Company's new cGMP life science production facility located at Viral Antigens, Inc., Memphis, TN (VAI), a wholly owned subsidiary. Under the terms of the agreement, VAI will optimize manufacturing processes and produce a specific insect cell-derived recombinant protein for its contract partner. This recombinant protein will be VA... 
 Printer Friendly Version
3/24/2003Japanese Multicenter Study of Meridian HpSA -- Stomach Ulcers -- Test Supports Usefulness in Diagnosing Pediatric Infections
CINCINNATI, Mar 24, 2003 (BUSINESS WIRE) -- Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced the publication, in The American Journal of Gastroenterology, of an important multicenter clinical study of Meridian's Premier Platinum HpSA(R) Test (HpSA) conducted in leading childrens' hospitals in Japan. The study, performed by the Japanese Pediatric HpSA Study Group, was designed to evaluate the diagnostic accuracy of Meridian's HpSA test in Japanese children. Based upon the results of... 
 Printer Friendly Version
2/19/2003Dr. K. John Morrow, Jr., Noted Geneticist and Molecular Biologist, Joins Meridian Bioscience, Inc.
CINCINNATI, Feb 19, 2003 (BUSINESS WIRE) -- Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that Dr. K. John Morrow, Jr. has joined its expanding scientific team. Prior to Meridian, Dr. Morrow was Professor of Cell Biology and Biochemistry at Texas Tech University Health Sciences Center in Lubbock, Texas. Dr. Morrow's research expertise is in the field of genetics and molecular systems for immunology. His current research is in the area of genetically engineered a... 
 Printer Friendly Version
1/21/2003Meridian Bioscience Reports Record Sales and Record First Quarter Operating Income, Declares Higher Regular Cash Dividend, and Reaffirms Fiscal 2003 Guidance
BIOWIRE2K CINCINNATI--(BUSINESS WIRE)--Jan. 21, 2003--Meridian Bioscience, Inc. (Nasdaq:VIVO) today: reported record quarterly net sales of $16,103,000 resulting in net earnings of $1,424,000 ($0.10 per diluted share) for the first quarter ended December 31, 2002: net sales were an all time record for any quarter in the Company's history; declared a regular quarterly cash dividend of $0.09 per share, $0.02 per share higher (+29%) tha... 
 Printer Friendly Version
1/15/2003Meridian Awarded New Patent for Novel Transport Device
CINCINNATI--(BUSINESS WIRE)--Jan. 15, 2003--Meridian Bioscience, Inc., (Nasdaq:VIVO) today announced that it has received from the U.S. Patent and Trademark Office the official Notice of Allowance for a patent entitled "Biological Sampling and Storage Container Utilizing a Desiccant". The patent relates to a device for the sampling and storing of specific biological samples used in medical testing. This allowance compliments a patent that was granted earlier (Patent No. 6,29... 
 Printer Friendly Version
1/9/2003Meridian's E. Coli Toxin Test Granted New Claim
BIOWIRE2K CINCINNATI--(BUSINESS WIRE)--Jan. 9, 2003--Meridian Bioscience, Inc., Cincinnati, Ohio (Nasdaq:VIVO) today announced that it has been granted FDA clearance to market an additional claim related to its ImmunoCard STAT!(R) E. coli 0157 Plus. This test identifies the most dangerous Shiga toxin-producing E. coli bacteria that can cause severe kidney damage or death, especially in infected children under 5 years of age. This new claim will enable the toxin-pro... 
 Printer Friendly Version